The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes

Rubina A. Heptulla, Luisa M. Rodriguez, Lisa Bomgaars, Morey W. Raymond

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes. We hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period. A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus-to-carbohydrate ratio during a standard liquid meal. Type 1 diabetic subjects were then randomized to two open-labeled studies. On one occasion, type 1 diabetic subjects received a 60% increase in the insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30-45 μg pramlintide with their usual insulin bolus-to-carbohydrate ratio. Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min. The plasma glucose area under the curve (AUC) for 0-420 min was lower in control versus type 1 diabetic subjects (316 ± 5 vs. 929 ± 18 mg · h -1 · dl-1, P < 0.0001). Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC 0-180 min 470 ± 43 vs. 434 ± 48 mg · h -1 · dl-1, P < 0.01). Pramlintide administration suppressed glucagon (P < 0.02), and glucagon injections prevented late hypoglycemia with increased insulin. In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings.

Original languageEnglish (US)
Pages (from-to)1100-1107
Number of pages8
JournalDiabetes
Volume54
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Glucagon
Type 1 Diabetes Mellitus
Insulin
Postprandial Period
Carbohydrates
Hypoglycemia
Hyperglycemia
Area Under Curve
Glucose
Injections
Meals
pramlintide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. / Heptulla, Rubina A.; Rodriguez, Luisa M.; Bomgaars, Lisa; Raymond, Morey W.

In: Diabetes, Vol. 54, No. 4, 04.2005, p. 1100-1107.

Research output: Contribution to journalArticle

Heptulla, Rubina A. ; Rodriguez, Luisa M. ; Bomgaars, Lisa ; Raymond, Morey W. / The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. In: Diabetes. 2005 ; Vol. 54, No. 4. pp. 1100-1107.
@article{1869f6facfb24d5cb74efc488eee2f0f,
title = "The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes",
abstract = "Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes. We hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period. A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus-to-carbohydrate ratio during a standard liquid meal. Type 1 diabetic subjects were then randomized to two open-labeled studies. On one occasion, type 1 diabetic subjects received a 60{\%} increase in the insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30-45 μg pramlintide with their usual insulin bolus-to-carbohydrate ratio. Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min. The plasma glucose area under the curve (AUC) for 0-420 min was lower in control versus type 1 diabetic subjects (316 ± 5 vs. 929 ± 18 mg · h -1 · dl-1, P < 0.0001). Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC 0-180 min 470 ± 43 vs. 434 ± 48 mg · h -1 · dl-1, P < 0.01). Pramlintide administration suppressed glucagon (P < 0.02), and glucagon injections prevented late hypoglycemia with increased insulin. In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings.",
author = "Heptulla, {Rubina A.} and Rodriguez, {Luisa M.} and Lisa Bomgaars and Raymond, {Morey W.}",
year = "2005",
month = "4",
doi = "10.2337/diabetes.54.4.1100",
language = "English (US)",
volume = "54",
pages = "1100--1107",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes

AU - Heptulla, Rubina A.

AU - Rodriguez, Luisa M.

AU - Bomgaars, Lisa

AU - Raymond, Morey W.

PY - 2005/4

Y1 - 2005/4

N2 - Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes. We hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period. A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus-to-carbohydrate ratio during a standard liquid meal. Type 1 diabetic subjects were then randomized to two open-labeled studies. On one occasion, type 1 diabetic subjects received a 60% increase in the insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30-45 μg pramlintide with their usual insulin bolus-to-carbohydrate ratio. Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min. The plasma glucose area under the curve (AUC) for 0-420 min was lower in control versus type 1 diabetic subjects (316 ± 5 vs. 929 ± 18 mg · h -1 · dl-1, P < 0.0001). Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC 0-180 min 470 ± 43 vs. 434 ± 48 mg · h -1 · dl-1, P < 0.01). Pramlintide administration suppressed glucagon (P < 0.02), and glucagon injections prevented late hypoglycemia with increased insulin. In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings.

AB - Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes. We hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period. A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus-to-carbohydrate ratio during a standard liquid meal. Type 1 diabetic subjects were then randomized to two open-labeled studies. On one occasion, type 1 diabetic subjects received a 60% increase in the insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30-45 μg pramlintide with their usual insulin bolus-to-carbohydrate ratio. Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min. The plasma glucose area under the curve (AUC) for 0-420 min was lower in control versus type 1 diabetic subjects (316 ± 5 vs. 929 ± 18 mg · h -1 · dl-1, P < 0.0001). Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC 0-180 min 470 ± 43 vs. 434 ± 48 mg · h -1 · dl-1, P < 0.01). Pramlintide administration suppressed glucagon (P < 0.02), and glucagon injections prevented late hypoglycemia with increased insulin. In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings.

UR - http://www.scopus.com/inward/record.url?scp=15944409169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944409169&partnerID=8YFLogxK

U2 - 10.2337/diabetes.54.4.1100

DO - 10.2337/diabetes.54.4.1100

M3 - Article

C2 - 15793249

AN - SCOPUS:15944409169

VL - 54

SP - 1100

EP - 1107

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -